MindMed (NEO: MMED) is moving up to the big leagues. The psychedelics company this morning announced that it has been approved for listing on the Nasdaq Capital Market.
Trading of the company on the big board is expected to begin on April 27, with the company to be listed under the symbol “MNMD”. The company is expected to continue to be listed on the Neo Exchange in Canada as well, with its symbol remaining unchanged.
Commenting on the achievement, CEO JR Rahn stated, “We believe this listing will increase our visibility in the marketplace, improve liquidity, broaden and diversify our shareholder base, and ultimately enhance long-term shareholder value.”
MindMed last traded at $2.67 on the Neo.
Information for this briefing was found via Sedar and MindMed. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
